NCT01499004 - A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Healthy

Interventions

DRUG

tofacitinib (CP-690,550) modified-release formulation A

A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.

DRUG

tofacitinib (CP-690,550) modified-release formulation B1

A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food

DRUG

tofacitinib (CP-690,550) modified-release formulation A

A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food

DRUG

tofacitinib (CP-690,550) modified-release formulation B1

A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food

DRUG

tofacitinib (CP-690,550) modified-release formulation B2

A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food

DRUG

tofacitinib (CP-690,550) immediate-release formulation

A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food

Trial Locations (1)

Pfizer Investigational Site, Singapore